BioSpace News Archive

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into securities purchase agreements with new and existing investors and certain directors and officers in a registered direct offering of 31,746,030 shares of common stock (the “Shares”) at a purchase price of $3.15 per share.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™.

Integer Holdings Corporation announced that it plans to release financial and operational results for second quarter 2022, at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, July 28, 2022.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.

Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully effective.

Vaxart, Inc. (Nasdaq: VXRT) today announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan plc (AIM: ORPH) under which hVIVO will conduct a characterization study and, if successful, develop a human challenge model based on the Omicron variant of SARS-CoV-2.

Smith+Nephew (LSE: SN), (NYSE: SNN), the global medical technology company, today announces the first robotic-assisted surgery using its LEGION CONCELOC Cementless Total Knee System was performed by Dr. Cyna Khalily, an orthopaedic surgeon specializing in adult reconstructive surgery of the hip and knee in Louisville, KY.

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced it has dosed its first subject in the open-label extension (OLE) for its Phase 2b trial of RIST4721 in palmoplantar pustulosis (PPP).

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 4, 2022.

Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Laura Mantell has joined its leadership team as Vice President of Life Sciences.